Key clinical point: Continued meloxicam treatment was associated with better pain scores at 4 weeks compared with switching to placebo.
Major finding: WOMAC pain scores (0-20) were 6.7 for patients who continued meloxicam versus 7.8 in those who stopped and switched to a placebo.
Study details: The Stopping NSAIDs for Arthritis Pain multicenter randomized withdrawal trial conducted in 364 patients with knee osteoarthritis treated with meloxicam, or with placebo followed by cognitive behavioral therapy.
Disclosures: The lead author disclosed receiving research funding from the VA Office of Research and Development, the sponsor of the trial.
Fraenkel L et al. JAMA Intern Med. 2020 Jul 20. doi: 10.1001/jamainternmed.2020.2821.